Beam Therapeutics Inc. (BEAM) shares ended the last trading session 5.7% higher at $21.46. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.3% gain over the past four weeks.The sudden price rise can be attributed to growing investors’ optimism surrounding the company’s promising pipeline. Last month, the FDA granted orphan drug designation to Beam Therapeutics’ investigational genome-editing candidate, BEAM-101, ...

BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at ...

Intellia Therapeutics (NTLA) incurred a loss of $1.10 per share (including one-time expenses of change in fair value of investments) in the first quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.26. In the year-ago quarter, the company had incurred a loss of $1.12 per share.The company’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of $16.6 million for the first quarter of 2025. Revenues declined 42.6% on a year-over-year basi ...

Beam Therapeutics (BEAM) reported a loss of $1.24 per share for the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of $1.11. The company had reported a loss of $1.21 per share in the year-ago quarter.Total revenues, comprising license and collaboration revenues, came in at $7.5 million in the first quarter compared with $7.4 million reported a year ago. The top line also missed the Zacks Consensus Estimate of $15 million. (Find the latest EPS estimates and surprises on Za ...

Caribou Biosciences, Inc. contacts: Investors: Amy Figueroa, CFA investor.relations@cariboubio.com Media: Peggy Vorwald, PhD media@cariboubio.com BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PD ...